Drug combination for stage IV melanoma shows success in trial
A new study examined the combination of the common immunotherapy drug pembrolizumab (Keytruda) with all-trans retinoic acid (ATRA), a chemotherapy drug that targets myeloid-derived suppressor cells. Researchers found that the drug combination is effective, with an overall response rate of 71%. Fifty percent of patients experienced a complete response, and the one-year overall survival rate was 80%.
Materials provided by University of Colorado Anschutz Medical Campus. Note: Content may be edited for style and length.
Source link aaaaa